Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
出版年份 2019 全文链接
标题
Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
作者
关键词
Breast cancer, Cancer treatment, Cell proliferation, Estrogens, Gene expression, Luciferase, MTT assay, MicroRNAs
出版物
PLoS One
Volume 14, Issue 5, Pages e0217181
出版商
Public Library of Science (PLoS)
发表日期
2019-05-24
DOI
10.1371/journal.pone.0217181
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- HuR facilitates cancer stemness of lung cancer cells via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis
- (2018) Yu Zhang et al. BIOTECHNOLOGY LETTERS
- Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer
- (2018) Juan Gu et al. CANCER LETTERS
- Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells
- (2018) Lijun Mo et al. CANCER SCIENCE
- MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1
- (2018) Xiu-Feng Gong et al. EXPERIMENTAL CELL RESEARCH
- Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis
- (2018) Jiaji Ding et al. EXPERIMENTAL CELL RESEARCH
- Down-regulation of Forkhead box protein A1 (FOXA1) leads to cancer stem cell-like properties in tamoxifen-resistant breast cancer cells through induction of interleukin-6
- (2017) Noritaka Yamaguchi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nuclear respiratory factor-1 and bioenergetics in tamoxifen-resistant breast cancer cells
- (2016) Brandie N. Radde et al. EXPERIMENTAL CELL RESEARCH
- Natural Products as Promising Antitumoral Agents in Breast Cancer: Mechanisms of Action and Molecular Targets.
- (2016) Daniela Bonofiglio et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop
- (2016) Xiunan Li et al. TUMOR BIOLOGY
- Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway
- (2015) Hongyan Wu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib
- (2015) WEN-JIE WANG et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway
- (2014) Jing-Tao Zhang et al. BMC CANCER
- Inhibition of Cdk2 kinase activity selectively targets the CD44+/CD24−/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells
- (2014) MATEUSZ OPYRCHAL et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- CDK3 expression and its clinical significance in human nasopharyngeal carcinoma
- (2014) LIANG WANG et al. Molecular Medicine Reports
- MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells
- (2014) J Cui et al. ONCOGENE
- miRNA Dysregulation in Breast Cancer
- (2013) L. Mulrane et al. CANCER RESEARCH
- Norcantharidin, Derivative of Cantharidin, for Cancer Stem Cells
- (2013) Chen-Hsi Hsieh et al. Evidence-based Complementary and Alternative Medicine
- Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells
- (2012) J. Cui et al. CANCER RESEARCH
- MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications
- (2012) Wei Tian et al. Clinical & Translational Oncology
- Clinical Applications for microRNAs in Cancer
- (2012) S P Nana-Sinkam et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Small-Molecule Synthetic Compound Norcantharidin Reverses Multi-Drug Resistance by Regulating Sonic Hedgehog Signaling in Human Breast Cancer Cells
- (2012) Yu-Jen Chen et al. PLoS One
- Estrogen Carcinogenesis in Breast Cancer
- (2011) Doris Germain ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Mechanisms of Endocrine Resistance in Breast Cancer
- (2010) C. Kent Osborne et al. Annual Review of Medicine
- FBI-1 functions as a novel AR co-repressor in prostate cancer cells
- (2010) Jiajun Cui et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells
- (2010) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Estrogen Receptor-α Phosphorylation at Serine-118 and Tamoxifen Response in Breast Cancer
- (2009) Marleen Kok et al. JNCI-Journal of the National Cancer Institute
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started